axitinib,sunitinib,pembrolizumab
merck,pfizer
['key,note,42', 'pembro', 'keynote-426', 'key,note,426']
dr. reported updated analysis of ph3keynote-426 with 5y minimum fu. efficacy is maintained. highlights on the post-hoc analysis of os and pfs on those that completed 35 cycles of pembro, with 70.7% alive at 5y. #asco23 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer